Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease
Global Heart · 2024
DOI: 10.5334/gh.1374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Heart, 2024. Verfasst von Hua Di und 5 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Medicine Center, Department of Acupuncture & Massage, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medica…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Coronary Artery Disease, Genetic Predisposition to Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical and Health Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Background
Epidemiological and clinical studies have shown that there is a co-morbidity between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD).
Methods
In this study, we utilized linkage disequilibrium score regression (LDSC) to evaluate the genetic correlation between non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD). We identified pleiotropic loci and genes using SNP-Level PLACO analysis. Following this, MAGMA gene set enrichment analysis was conducted to assess the biological significance of these pleiotropic genes. Finally, a two-sample two-way Mendelian randomization (MR) analysis was performed to evaluate causal relationships between NAFLD and CAD.
Results
We found a significant genetic correlation between NAFLD and CAD. Secondly, PLACO multi-effect analysis identified 6 sites (mainly involved in the establishment of chylomicrons, mitochondrial membrane protein localization and herpes simplex virus 1 infection signaling pathway). Then, three pleiotropic genes (APOC1, TOMM40 and PBX4) were identified by MAGMA gene analysis. Finally, a two-sample two-way MR analysis suggested that there was no causal relationship between NAFLD and CAD.
Conclusions
Our results show that there are significant gene overlaps and pleiotropic genes between NAFLD and CAD and point out their common molecular mechanisms. These findings provide evidence for the common etiology between them and also help to better understand the pleiotropic nature between NAFLD and CAD, which may be of guiding significance for future treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatric Medicine Center, Department of Acupuncture & Massage, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
- Hepatology Diagnosis and Treatment Center, The First Affiliated Hospital of Wenzhou Medical University and Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, Wenzhou 32503…
- Center for General Practice Medicine, Department of Infectious Diseases, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
- Centre for Cancer & Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
ORCID-Profile: Hua Di, Shouhao Wang, Chengan Xu, Qiaoqiao Yin, Keyang Xu, Wei Zheng
Förderung
- Medical and Health Science and Technology Project of Zhejiang Province
Zitieren
APA
Di, H., Wang, S., Xu, C., Yin, Q., Xu, K., & Zheng, W. (2024). Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease. Global Heart. https://doi.org/10.5334/gh.1374
Vancouver
Di H, Wang S, Xu C, Yin Q, Xu K, Zheng W. Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease. Global Heart. 2024. doi:10.5334/gh.1374
BibTeX
@article{Di2024,
author = {Di, Hua and Wang, Shouhao and Xu, Chengan and Yin, Qiaoqiao and Xu, Keyang and Zheng, Wei},
title = {Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease},
journal = {Global Heart},
year = {2024},
doi = {10.5334/gh.1374}
}
EUVIMED